The AZGP1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the widely utilized HeLa human epithelial adenocarcinoma cell line, engineered to disrupt the AZGP1 gene and abolish its protein expression. This product comprises a heterogeneous mix of cells, each harboring a targeted disruption in the AZGP1 locus, generated through a transient CRISPR/Cas9 editing process without single-cell cloning. The polyclonal nature ensures biological diversity, reflecting a pool of edited genotypes that collectively eliminate wild-type AZGP1 function, making it a versatile tool for loss-of-function studies. AZGP1 gene disruption is achieved via guide RNA-directed Cas9 cleavage, resulting in a frameshift mutation that effectively knocks out the gene??s coding potential across the cell population. This format minimizes clonal artifacts and provides a robust model for investigating AZGP1??s roles in cellular pathways relevant to cancer and metabolic research.
HeLa cells, the host for this knockout model, are an immortalized cell line originating from a cervical adenocarcinoma of Henrietta Lacks, and have been a cornerstone of biomedical research for decades. These cells exhibit an epithelial morphology, robust proliferation, and a well-characterized genomic landscape, making them highly amenable to gene editing and functional assays. As a cervical cancer-derived line, HeLa retains oncogenic traits such as aberrant signaling networks and metabolic reprogramming, providing a clinically relevant platform to study cancer biology. Their broad use in signal transduction, drug discovery, and tumor microenvironment research ensures a wealth of established protocols, enabling seamless integration of this AZGP1 knockout into existing experimental workflows.
AZGP1, encoding zinc-alpha-2-glycoprotein, is a multifunctional secreted protein involved in lipid metabolism and immune regulation. Its expression is transcriptionally activated by PPAR?? and androgens, and it is responsive to inflammatory cytokines such as TNF-??, placing it at the convergence of metabolic and immune signaling. The protein interacts with zinc ions and forms complexes with ??2-microglobulin and MHC class I molecules, facilitating lipid mobilization and antigen presentation. Downstream, AZGP1 modulates hormone-sensitive lipase activity, promoting lipid breakdown, and influences GLUT4 translocation to regulate glucose uptake; it also impinges on NF-??B signaling to modulate cytokine responses. Thus, AZGP1 acts as a molecular bridge, coordinating metabolic adjustment and immune surveillance, with the knockout disrupting these critical pathways.
In HeLa cells, loss of AZGP1 disrupts its role in lipid metabolism and immune modulation, creating a powerful model to dissect its functions in a cancer context. Since HeLa originates from an adenocarcinoma, the knockout enables study of how AZGP1 deficiency affects tumor cell lipid storage, energy homeostasis, and immune evasion mechanisms. This is particularly relevant given AZGP1??s associations with obesity, type 2 diabetes, and cancers such as prostate, breast, and hepatocellular carcinoma. The polyclonal population maintains genetic heterogeneity, allowing investigation of diverse loss-of-function phenotypes while avoiding clonal bias. This model thus serves as a valuable in vitro system to explore the intersection of metabolic dysregulation and cancer progression.
Researchers can employ this AZGP1 knockout HeLa cell population in a broad range of experimental applications. Key studies include analyzing lipid accumulation using Oil Red O or BODIPY staining, assessing alterations in hormone-sensitive lipase expression via western blotting, and quantifying changes in NF-??B reporter activity or cytokine secretion profiles. RT-qPCR can validate transcriptional changes in downstream targets like GLUT4, while immunofluorescence microscopy permits localization studies of AZGP1-associated complexes. The model is ideal for investigating tumor microenvironment interactions, metabolic reprogramming, and immune evasion, with representative assays extending to apoptosis (Annexin V staining) and migration (Transwell assays). For additional details or ordering information, please contact Ascent Research.
